- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04770350
Open Label Study for the Use of Transcranial Ultrasound for Treatment of Age-Related Frailty (fUS-ARF)
September 26, 2022 updated by: Neurological Associates of West Los Angeles
The purpose of this Phase I open label study is to evaluate longer term tolerability and potential effectiveness of transcranial ultrasound in people with age-related frailty.
Study Overview
Status
Enrolling by invitation
Intervention / Treatment
Detailed Description
This study is designed to evaluate the safety and efficacy of focused ultrasound in patients with age-related frailty characterized by reduced physical and immunological functioning.
The safety of this protocol will be closely monitored and data will be used to determine whether any significant safety issues exist when using focused ultrasound.
Adverse events will be noted whenever they occur but will be recorded at the time of the procedure and throughout routine follow-ups, which will persist weekly throughout the duration of the active study protocol.
Patients deemed potentially appropriate candidates for focused ultrasound therapy will be treated with 8 sessions of transcranial ultrasound, each of which consists of 10 to 30 minutes of active administration.
Clinical and safety outcome measures will be obtained throughout and after completion of the study protocol.
Study Type
Interventional
Enrollment (Anticipated)
50
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Santa Monica, California, United States, 90403
- Neurological Associates of West Los Angeles
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
45 years to 95 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age eligibility requirements fall in a range from 60 to 95 years of age
- Clinical appraisal by physician indicating signs of frailty (apart from a co-occuring condition), scoring 3<x<7 as denoted by the CSHA Clinical Frailty Scale (Rockwood, Song, MacKnight, et al, 2005; Golpanian, DiFede, Pujol, et al., 2016)
- MRI of the brain including volume measurement of the hypothalamus
Exclusion Criteria:
- Subjects unable to give informed consent
- Subjects who would not be able to lay down without excessive movement in a calm environment sufficiently long enough to be able to achieve sleep
- Pregnancy, women who may become pregnant or are breastfeeding
- Advanced terminal illness
- Subjects with scalp rash or open wounds on the scalp (for example from treatment of squamous cell cancer)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental
Participants will undergo ten to thirty minutes of transcranial ultrasound treatment.
The sanitation device will be aimed at the hypothalamus.
Targeting will include reference to scalp fiducials based on the obtained MRI; confirmation of target accuracy will either be obtained by Doppler waveform confirmation or optical tracking technology which co-registers patient neuroimaging with real space.
|
The DWL Doppler ultrasound device enables visual and auditory waveform confirmation of the middle cerebral artery, and optical tracking technology (e.g., AntNeuro Visor2™ system) may be used in tandem with the Brainsonix ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Frailty Scale (CFS)
Time Frame: Baseline
|
The CFS is a 9-point scoring guide for physicians to use upon clinical appraisal of frailty-related symptoms.
The lowest rating is 1 ("Very Fit") and the highest rating is 9 ("Terminally Ill").
The range of acceptable ratings for screened participants is from 3 ("Managing Well") to 7 ("Severely Frail").
|
Baseline
|
Clinical Frailty Scale (CFS)
Time Frame: Final Evaluation (8 weeks from baseline)
|
The CFS is a 9-point scoring guide for physicians to use upon clinical appraisal of frailty-related symptoms.
The lowest rating is 1 ("Very Fit") and the highest rating is 9 ("Terminally Ill").
The range of acceptable ratings for screened participants is from 3 ("Managing Well") to 7 ("Severely Frail").
Scoring on the CFS will be noted as significant for those who improve by at least one level.
|
Final Evaluation (8 weeks from baseline)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Montreal Cognitive Assessment (MoCA)
Time Frame: Baseline
|
The MoCA evaluates frontal-executive functions (e.g., verbal abstraction and mental calculation), language (e.g., confrontation naming, phonemic fluency), orientation (e.g., person, place, date, day of the week, and time), visuospatial construction (e.g., simple figure copy), divided visual attention, and immediate and delayed memory of unstructured information.
MoCA scores range from 0-30 possible points; 26 or greater is considered to reflect normal cognitive status.
|
Baseline
|
Beck Anxiety Inventory (BAI)
Time Frame: Baseline
|
The BAI is a 21-question multiple-choice self-report inventory that is used for measuring the severity of anxiety symptoms.
Each of the 21 items asks whether the patient has experienced various anxiety symptoms in the last two weeks, and if so, how severely.
Each question/answer is scored on a scale value of "0" (not at all) to "3" (severely).
Higher total scores indicate more severe anxiety symptoms.
The maximum total score possible is 63 points.
The standard cutoff scores are: 0-7 = minimal anxiety; 8-15 = mild anxiety; 16-25 = moderate anxiety; 26-63 = severe anxiety.
A reduction in score by at least 30% is considered clinically meaningful.
|
Baseline
|
Beck Depression Inventory (BDI-II)
Time Frame: Baseline
|
The BDI-II is a 21-question multiple-choice self-report inventory.
Each question involves four possible responses, ranging in intensity from "0" (this item does not apply) to "3" (this item applies severely).
The test is scored as the sum of all of the response values; this number is used to determine the severity of depressive symptoms.
A score of 0 to 3 is possible for each question with a maximum total score of 63 points.
The standard cutoff scores are as follows: 0-13 total points = minimal depression; 14-19 total points = mild depression; 20-28 total points = moderate depression; and 29-63 total points = severe depression.
A reduction in the total score by at least 30% is considered to be clinically significant.
|
Baseline
|
Short Physical Performance Battery (SPPB)
Time Frame: Baseline
|
The SPPB is a series of tests used to evaluate lower extremity function and mobility in older people.
The test consists of three major components, each of which are scored independently: 3 static balance tests, gait speed, and five timed sit-to-stand tests.
Points are assigned based on performance, with a maximum possible score of 12 points.
Higher scores are indicative of better functioning.
A score of 0 on any item indicates lack of ability or functioning.
The minimum clinically important difference for the total SPPB score is 1 point.
|
Baseline
|
Short Physical Performance Battery (SPPB)
Time Frame: Final Evaluation (8 weeks from baseline)
|
The SPPB is a series of tests used to evaluate lower extremity function and mobility in older people.
The test consists of three major components, each of which are scored independently: 3 static balance tests, gait speed, and five timed sit-to-stand tests.
Points are assigned based on performance, with a maximum possible score of 12 points.
Higher scores are indicative of better functioning.
A score of 0 on any item indicates lack of ability or functioning.
The minimum clinically important difference for the total SPPB score is 1 point.
|
Final Evaluation (8 weeks from baseline)
|
Multidimensional Fatigue Inventory (MFI)
Time Frame: Baseline
|
The MFI is a 20-item scale designed to evaluate five dimensions of fatigue: general fatigue, physical fatigue, reduced motivation, reduced activity, and mental fatigue.
Respondents use a scale ranging from 1 to 7 to indicate how aptly certain statements regarding fatigue represent their experiences.
Several positively phrased items are reverse- scored.
Higher total scores correspond with more acute levels of fatigue.
Responses for the Multidimensional Fatigue Inventory will be defined as clinically significant when there is a 2-point difference.
|
Baseline
|
Multidimensional Fatigue Inventory (MFI)
Time Frame: Final Evaluation (8 weeks from baseline)
|
The MFI is a 20-item scale designed to evaluate five dimensions of fatigue: general fatigue, physical fatigue, reduced motivation, reduced activity, and mental fatigue.
Respondents use a scale ranging from 1 to 7 to indicate how aptly certain statements regarding fatigue represent their experiences.
Several positively phrased items are reverse- scored.
Higher total scores correspond with more acute levels of fatigue.
Responses for the Multidimensional Fatigue Inventory will be defined as clinically significant when there is a 2-point difference.
|
Final Evaluation (8 weeks from baseline)
|
Montreal Cognitive Assessment (MoCA)
Time Frame: Final Evaluation (8 weeks from baseline)
|
The MoCA evaluates frontal-executive functions (e.g., verbal abstraction and mental calculation), language (e.g., confrontation naming, phonemic fluency), orientation (e.g., person, place, date, day of the week, and time), visuospatial construction (e.g., simple figure copy), divided visual attention, and immediate and delayed memory of unstructured information.
MoCA scores range from 0-30 possible points; 26 or greater is considered to reflect normal cognitive status.
|
Final Evaluation (8 weeks from baseline)
|
Beck Depression Inventory (BDI-II)
Time Frame: Final Evaluation (8 weeks from baseline)
|
The BDI-II is a 21-question multiple-choice self-report inventory.
Each question involves four possible responses, ranging in intensity from "0" (this item does not apply) to "3" (this item applies severely).
The test is scored as the sum of all of the response values; this number is used to determine the severity of depressive symptoms.
A score of 0 to 3 is possible for each question with a maximum total score of 63 points.
The standard cutoff scores are as follows: 0-13 total points = minimal depression; 14-19 total points = mild depression; 20-28 total points = moderate depression; and 29-63 total points = severe depression.
A reduction in the total score by at least 30% is considered to be clinically significant.
|
Final Evaluation (8 weeks from baseline)
|
Beck Anxiety Inventory (BAI)
Time Frame: Final Evaluation (8 weeks from baseline)
|
The BAI is a 21-question multiple-choice self-report inventory that is used for measuring the severity of anxiety symptoms.
Each of the 21 items asks whether the patient has experienced various anxiety symptoms in the last two weeks, and if so, how severely.
Each question/answer is scored on a scale value of "0" (not at all) to "3" (severely).
Higher total scores indicate more severe anxiety symptoms.
The maximum total score possible is 63 points.
The standard cutoff scores are: 0-7 = minimal anxiety; 8-15 = mild anxiety; 16-25 = moderate anxiety; 26-63 = severe anxiety.
A reduction in score by at least 30% is considered clinically meaningful.
|
Final Evaluation (8 weeks from baseline)
|
Community Healthy Activities Model Program for Seniors (CHAMPS)
Time Frame: Baseline
|
This self-report questionnaire assesses weekly frequency and duration of a variety of lifestyle physical activities that are meaningful and appropriate for older adults.
It includes activities of various intensities (from light to vigorous) such as walking, running, hiking, swimming, bicycling, dancing, tennis, aerobics, yoga/tai chi, gardening, and housework.
Intensity is reflected in the item stem (e.g., light and heavy gardening are separate items).
The questionnaire is self-administered, although it can be interviewer administered.
It is formatted to accommodate increasing visual problems with age by using a large font, adequate space on the page, and high contrast.
A total caloric expenditure is calculated based on reported participant activity.
Responses for the CHAMPS questionnaire will be defined as clinically significant when there is a 8 kcal/kg/week difference.
|
Baseline
|
Community Healthy Activities Model Program for Seniors (CHAMPS)
Time Frame: Final Evaluation (8 weeks from baseline)
|
This self-report questionnaire assesses weekly frequency and duration of a variety of lifestyle physical activities that are meaningful and appropriate for older adults.
It includes activities of various intensities (from light to vigorous) such as walking, running, hiking, swimming, bicycling, dancing, tennis, aerobics, yoga/tai chi, gardening, and housework.
Intensity is reflected in the item stem (e.g., light and heavy gardening are separate items).
The questionnaire is self-administered, although it can be interviewer administered.
It is formatted to accommodate increasing visual problems with age by using a large font, adequate space on the page, and high contrast.
A total caloric expenditure is calculated based on reported participant activity.
Responses for the CHAMPS questionnaire will be defined as clinically significant when there is a 8 kcal/kg/week difference.
|
Final Evaluation (8 weeks from baseline)
|
Grip Strength (Dynamometer Performance)
Time Frame: Baseline
|
Participants will be asked to demonstrate grip strength in standard fashion for clinical evaluation.
Using the JAMAR Technologies Hydraulic Hand Dynamometer, participants will squeeze the instrument with their dominant hand and generate a reading of grip strength in the output reading (units = kg).
The MCID of the grip strength test is a change of at least 5.0 kg.
|
Baseline
|
Grip Strength (Dynamometer Performance)
Time Frame: Final Evaluation (8 weeks from baseline)
|
Participants will be asked to demonstrate grip strength in standard fashion for clinical evaluation.
Using the JAMAR Technologies Hydraulic Hand Dynamometer, participants will squeeze the instrument with their dominant hand and generate a reading of grip strength in the output reading (units = kg).
The MCID of the grip strength test is a change of at least 5.0 kg.
|
Final Evaluation (8 weeks from baseline)
|
Global Rating of Change (GRC)
Time Frame: Final Evaluation (8 weeks from baseline)
|
The GRC consists of a single likert-scale ranging from "-5" (very much worse) to "0" (neutral/no change) to "5" (very much better).
The GRC is obtained in an interview format to assess a patient's perceived change in status following a treatment.
A score that is at least 2 or greater is considered to indicate clinically significant change.
|
Final Evaluation (8 weeks from baseline)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Sheldon Jordan, MD, Neurological Associates - the Interventional Group
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet. 2013 Mar 2;381(9868):752-62. doi: 10.1016/S0140-6736(12)62167-9. Epub 2013 Feb 8. Erratum In: Lancet. 2013 Oct 19;382(9901):1328.
- Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, Mitnitski A. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005 Aug 30;173(5):489-95. doi: 10.1503/cmaj.050051.
- Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013 Jun 6;153(6):1194-217. doi: 10.1016/j.cell.2013.05.039.
- Song X, Mitnitski A, Rockwood K. Prevalence and 10-year outcomes of frailty in older adults in relation to deficit accumulation. J Am Geriatr Soc. 2010 Apr;58(4):681-7. doi: 10.1111/j.1532-5415.2010.02764.x. Epub 2010 Mar 22.
- Tompkins BA, DiFede DL, Khan A, Landin AM, Schulman IH, Pujol MV, Heldman AW, Miki R, Goldschmidt-Clermont PJ, Goldstein BJ, Mushtaq M, Levis-Dusseau S, Byrnes JJ, Lowery M, Natsumeda M, Delgado C, Saltzman R, Vidro-Casiano M, Da Fonseca M, Golpanian S, Premer C, Medina A, Valasaki K, Florea V, Anderson E, El-Khorazaty J, Mendizabal A, Green G, Oliva AA, Hare JM. Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial. J Gerontol A Biol Sci Med Sci. 2017 Oct 12;72(11):1513-1522. doi: 10.1093/gerona/glx137.
- Zhang Y, Kim MS, Jia B, Yan J, Zuniga-Hertz JP, Han C, Cai D. Hypothalamic stem cells control ageing speed partly through exosomal miRNAs. Nature. 2017 Aug 3;548(7665):52-57. doi: 10.1038/nature23282. Epub 2017 Jul 26. Erratum In: Nature. 2018 Aug;560(7719):E33.
- Juma S, Taabazuing MM, Montero-Odasso M. Clinical Frailty Scale in an Acute Medicine Unit: a Simple Tool That Predicts Length of Stay. Can Geriatr J. 2016 Jun 29;19(2):34-9. doi: 10.5770/cgj.19.196. eCollection 2016 Jun.
- Islam A, Muir-Hunter SW, Speechley M, Montero-Odasso M. Facilitating Frailty Identification: Comparison of Two Methods among Community-Dwelling Order Adults. J Frailty Aging. 2014;3(4):216-21. doi: 10.14283/jfa.2014.27.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
September 1, 2023
Primary Completion (Anticipated)
September 30, 2024
Study Completion (Anticipated)
December 31, 2024
Study Registration Dates
First Submitted
February 22, 2021
First Submitted That Met QC Criteria
February 22, 2021
First Posted (Actual)
February 25, 2021
Study Record Updates
Last Update Posted (Actual)
September 28, 2022
Last Update Submitted That Met QC Criteria
September 26, 2022
Last Verified
September 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- fUS-Frailty
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Frailty
-
University of PennsylvaniaCompleted
-
Instituto Tecnologico y de Estudios Superiores...Not yet recruiting
-
Longeveron Inc.CompletedAging FrailtyUnited States
-
Longeveron Inc.CompletedAging FrailtyUnited States
-
The Hong Kong Polytechnic UniversityCompleted
-
Xijing HospitalUnknownFrailty SyndromeChina
-
Region ZealandUniversity of Southern DenmarkActive, not recruitingFrailty SyndromeDenmark
-
Neurological Associates of West Los AngelesEnrolling by invitation
-
IRCCS Centro San Giovanni di Dio FatebenefratelliCompleted
-
University of Erlangen-Nürnberg Medical SchoolCompleted
Clinical Trials on Focused Ultrasound
-
Shufang ChangRecruitingCervical Intraepithelial NeoplasiaChina
-
University of California, Los AngelesNational Institute on Aging (NIA)RecruitingMild Cognitive Impairment | Deep Brain Stimulation | Amnestic Mild Cognitive Disorder | Mild Alzheimer's DiseaseUnited States
-
Virginia Polytechnic Institute and State UniversitySalem VA Medical Center; Washington DC VA Medical CenterNot yet recruitingChronic Pain | Opioid Use Disorder | Anxiety DisorderUnited States
-
Virginia Polytechnic Institute and State UniversityEnrolling by invitation
-
University of California, San FranciscoCompletedUterine FibroidsUnited States
-
Marc Dall'Era, MDNational Cancer Institute (NCI)RecruitingLocalized Prostate Carcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8United States
-
Chongqing Medical UniversityRecruitingThe Therapeutic Effect of Low-intensity Focused Ultrasound on Painful Diabetic Peripheral NeuropathyPainful Diabetic NeuropathyChina
-
Philips HealthcareCompletedSecondary Malignant Neoplasm of BoneFrance
-
Virginia Polytechnic Institute and State UniversityNot yet recruiting
-
Medical University of South CarolinaNot yet recruiting